• InterView
• "Leclaza’s mOS data of 38.9 months is remarkable"
• by Kim, Jin-Gu Jul 4, 2022 05:55am

• InterView
• Tremfya to bring generation shift in the IL inhibitor market
• by Jun 23, 2022 05:50am

• InterView
• “Roche reborn through customer-centric reorganization”
• by Eo, Yun-Ho Jun 21, 2022 05:54am

• InterView
• Otrivin package made user-friendly for pharmacist & patient
• by Eo, Yun-Ho Jun 13, 2022 05:55am

• InterView
• “Allowing safe use of JAK inhibitors over restrictions"
• by Eo, Yun-Ho May 26, 2022 05:56am

• InterView
• We are making all efforts to reimburse ‘Vyndamax’
• by Eo, Yun-Ho Apr 21, 2022 06:03am

• InterView
• "Will make R&D partnerships, introduce new drugs in Korea"
• by Apr 14, 2022 05:56am

• InterView
• Sanofi introduces digital solutions for customers & patients
• by Eo, Yun-Ho Feb 22, 2022 05:55am

• InterView
• Era of ₩30 bil novel homegrown drug Suganon begins now
• by Feb 3, 2022 05:57am

• InterView
• There shouldn't be any patients who can't receive new drugs
• by Eo, Yun-Ho Jan 5, 2022 05:59am